Skip to main content
. Author manuscript; available in PMC: 2020 Sep 1.
Published in final edited form as: Toxicol Appl Pharmacol. 2019 Jun 6;378:114614. doi: 10.1016/j.taap.2019.114614

Fig. 7.

Fig. 7.

BUB1 levels respond to hsa-miR-186 overexpression and to arsenite exposure. (A) Western blots of BUB1, CDC27 and β-Actin in hsa-miR-186 overexpressing clones +/− 100 nM arsenite for 8 weeks. (B) Quantitation of BUB1 relative to β-Actin. Western blot and quantitation showing decreased expression of BUB1 in hsa-miR-186 overexpressing clones, arsenite increases BUB1 suppression. Statistical analysis by 2-Way ANOVA.